Guided Therapeutics, Inc.

GTHP

US40171F5017

Advanced Medical Equipment & Technology

Market Closed - OTC Markets Other stock markets 03:03:30 2024-06-11 pm EDT			5-day change	1st Jan Change
0.09 ^USD	0.00%		-10.00%	-41.37%

May. 14	Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 28	Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Guided Therapeutics, Inc Announces Resignation of Shabbir Bambot as Vice President of Research and Development

May 20, 2013 at 04:11 pm EDT

Guided Therapeutics Inc. announced that Shabbir Bambot resigned from his position as Vice President of Research and Development, effective May 10, 2013.

Latest news about Guided Therapeutics, Inc.

Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval	Nov. 20	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Guided Therapeutics, Inc. Announces CEO Changes	23-03-09	CI
Guided Therapeutics, Inc. Announces Executive Changes	23-03-09	CI
Guided Therapeutics Signs Agreement to Begin Clinical Trial for US FDA Approval	22-12-21	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Guided Therapeutics Provides Update of Significant Progress in Chinese Clinical Study for Marketing Approval of the LuViva Advanced Cervical Scan	22-11-09	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Guided Therapeutics, Inc. Receives Institutional Review Board Approval to Start Clinical Study for FDA Approval of the LuViva® Advanced Cervical Scan	22-07-20	CI
Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Guided Therapeutics, Inc. Announces Testing Completion of First 150 Patients in Chinese Clinical Study and Receives Milestone Payment of $177,740	22-03-31	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-03-29	CI
Guided Therapeutics, Inc. Announces Start of Chinese Clinical Trial for Approval to Market and Sell LuViva in China	21-11-17	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China	21-08-19	CI
Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-18	CI
Guided Therapeutics Receives News from Chinese State Food and Drug Administration that LuViva Meets Product Technical Requirements	21-07-20	CI
Guided Therapeutics, Inc. announced that it has received $1.13 million in funding	21-06-02	CI

Chart Guided Therapeutics, Inc.

Duration

Period

More charts

Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Companyâs primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
GUIDED THERAPEUTICS, INC.	-41.37%	5.01M
THERMO FISHER SCIENTIFIC	+8.50%	222B
INTUITIVE SURGICAL, INC.	+24.13%	148B
BOSTON SCIENTIFIC CORPORATION	+33.45%	114B
SIEMENS HEALTHINEERS AG	+4.45%	65.69B
EDWARDS LIFESCIENCES CORPORATION	+14.10%	51.88B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.08%	50.02B
AGILENT TECHNOLOGIES, INC.	-4.98%	38.81B
GE HEALTHCARE TECHNOLOGIES INC.	-3.34%	34.59B
RESMED, INC.	+22.18%	31.09B